Suspended

Cardiovascular Effects on Growth Hormone Replacement Therapy in Adults With Primary or Secondary Childhood Onset Growth Hormone Deficiency

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

somatropin

Drug
Who is being recruted

Bone Diseases+10

+ Bone Diseases, Developmental

+ Bone Diseases, Endocrine

From 12 to 25 Years
+4 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Phase 4
Interventional
Study Start: May 2001
See protocol details

Summary

Principal SponsorNovo Nordisk A/S
Last updated: February 27, 2017
Sourced from a government-validated database.Claim as a partner

Study start date: May 16, 2001

Actual date on which the first participant was enrolled.

This trial is conducted in Europe. The aim of this trial is to investigate the effect of growth hormone on left ventricle morphology and function (systolic and diastolic).

NCT01698944
Principal SponsorNovo Nordisk A/S
Last updated: February 27, 2017
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

7 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 12 to 25 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Bone DiseasesBone Diseases, DevelopmentalBone Diseases, EndocrineBrain DiseasesCentral Nervous System DiseasesDwarfismEndocrine System DiseasesHypopituitarismHypothalamic DiseasesMusculoskeletal DiseasesNervous System DiseasesPituitary DiseasesDwarfism, Pituitary

Criteria

2 inclusion criteria required to participate
Adult growth hormone deficiency
At least 2 years without growth hormone treatment
2 exclusion criteria prevent from participating
Pregnancy
Supine blood pressure above 160 mmHg systolic or above 100 mmHg diastolic

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

One single intervention group is designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Novo Nordisk Investigational Site

Athens, GreeceOpen Novo Nordisk Investigational Site in Google Maps
SuspendedOne Study Center